Search for Clinical Trial Results
Carcinoma, Neuroendocrine - 25 Studies Found
Status | Study |
Not yet recruiting |
Study Name: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas Condition: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) Date: 2017-04-18 Interventions:
|
Not yet recruiting |
Study Name: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Condition: Date: 2024-05-10 |
Completed |
Study Name: KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Condition: Carcinoma, Neuroendocrine Date: 2014-08-21 Interventions: Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE) |
Recruiting |
Study Name: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis Condition: Date: 2024-05-10 |
Recruiting |
Study Name: A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours Condition: Date: 2024-05-10 |
Completed |
Study Name: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Condition:
Date: 2005-06-07 Interventions:
|
Recruiting |
Study Name: SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Condition:
Date: 2015-07-06 Interventions: Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks |
Recruiting |
Study Name: Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin Condition: Neuroendocrine Carcinomas Date: 2016-02-18 Interventions: Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o |
Recruiting |
Study Name: Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Condition: Neuroendocrine Carcinoma Date: 2016-02-17 Interventions: Drug: Everolimus Maintenance therapy Other Name: Afi |
Active, not recruiting |
Study Name: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Condition: Neuroendocrine Carcinoma of the Lung and Thymus Date: 2012-03-20 Interventions:
|